RT Journal Article
SR Electronic
T1 Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.20.22281327
DO 10.1101/2022.10.20.22281327
A1 Embi, Peter J.
A1 Levy, Matthew E.
A1 Patel, Palak
A1 DeSilva, Malini B.
A1 Gaglani, Manjusha
A1 Dascomb, Kristin
A1 Dunne, Margaret M.
A1 Klein, Nicola P.
A1 Ong, Toan C.
A1 Grannis, Shaun J.
A1 Natarajan, Karthik
A1 Yang, Duck-Hye
A1 Stenehjem, Edward
A1 Zerbo, Ousseny
A1 McEvoy, Charlene
A1 Rao, Suchitra
A1 Thompson, Mark G.
A1 Konatham, Deepika
A1 Irving, Stephanie A.
A1 Dixon, Brian E.
A1 Han, Jungmi
A1 Schrader, Kristin E.
A1 Grisel, Nancy
A1 Lewis, Ned
A1 Kharbanda, Anupam B.
A1 Barron, Michelle A.
A1 Reynolds, Sue
A1 Liao, I-Chia
A1 Fadel, William F.
A1 Rowley, Elizabeth A.
A1 Arndorfer, Julie
A1 Goddard, Kristin
A1 Murthy, Kempapura
A1 Valvi, Nimish R.
A1 Weber, Zachary A.
A1 Fireman, Bruce
A1 Reese, Sarah E.
A1 Ball, Sarah W.
A1 Naleway, Allison L.
YR 2022
UL http://medrxiv.org/content/early/2022/10/21/2022.10.20.22281327.abstract
AB Background Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and are less protected by 1-2 COVID-19 vaccine doses than are immunocompetent (non-IC) persons. We compared vaccine effectiveness (VE) against medically attended COVID-19 of 2-3 mRNA and 1-2 viral-vector vaccine doses between IC and non-IC adults.Methods Using a test-negative design among eight VISION Network sites, VE against laboratory-confirmed COVID-19–associated emergency department (ED) or urgent care (UC) events and hospitalizations from 26 August-25 December 2021 was estimated separately among IC and non-IC adults and among specific IC condition subgroups. Vaccination status was defined using number and timing of doses. VE for each status (versus unvaccinated) was adjusted for age, geography, time, prior positive test result, and local SARS-CoV-2 circulation.Results We analyzed 8,848 ED/UC events and 18,843 hospitalizations among IC patients and 200,071 ED/UC events and 70,882 hospitalizations among non-IC patients. Among IC patients, 3-dose mRNA VE against ED/UC (73% [95% CI: 64-80]) and hospitalization (81% [95% CI: 76-86]) was lower than that among non-IC patients (ED/UC: 94% [95% CI: 93-94]; hospitalization: 96% [95% CI: 95-97]). Similar patterns were observed for viral-vector vaccines. Transplant recipients had lower VE than other IC subgroups.Conclusions During B.1.617.2 (Delta) variant predominance, IC adults received moderate protection against COVID-19–associated medical events from three mRNA doses, or one viral-vector dose plus a second dose of any product. However, protection was lower in IC versus non-IC patients, especially among transplant recipients, underscoring the need for additional protection among IC adults.Key points During Delta variant predominance, immunocompromised (IC) adults received moderate protection against COVID-19-associated medical events from three mRNA doses, but IC patients, especially transplant recipients, were less protected than non-IC patients, underscoring the need for additional protection beyond the primary series.Competing Interest StatementAll authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Nicola P. Klein reports institutional support from Pfizer for COVID-19 vaccine clinical trials. Charlene McEvoy reports institutional support from AstraZeneca for an AZD1222 COVID-19 vaccine trial. Suchitra Rao reports grant support from GlaxoSmithKline and Biofire Diagnostics. Dr. Brian Dixon reports past consulting fees from Merck & Co. for serving on an advisory panel for HPV vaccination. Manjusha Gaglani reports past support from the CDC for the IVY-3 vaccine research. Kempapura Murthy reports past support from the CDC HAIVEN - Hospitalized Adult Influenza Vaccine Effectiveness Network. All other authors report no disclosures relevant to the current manuscript.Funding StatementThis study was funded by the Centers for Disease Control and Prevention though contract 75D30120C07986 to Westat, Inc. and contract 75D30120C07765 to Kaiser Foundation Hospitals. Study sponsors placed no limitations on publication nor required confidentiality in reporting of resultsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Westat, Inc gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual level dataset from this study is held securely in limited deidentified form at the US Centers for Disease Control and Prevention. Data sharing agreements between CDC and data providers prohibit CDC from making this dataset publicly available. CDC will share aggregate study data once study objectives are complete, consistent with data use agreements with partner institutions.